Search Results - "Yeleswaram, Swamy"

Itacitinib Population Pharmacokinetics and Exposure‐Response in Patients With Acute Graft‐Versus‐Host Disease by Chen, Xuejun, Xun, Zhiyin, Yuska, Brad, McGee, Ryan, Yeleswaram, Swamy

“…This article presents the population pharmacokinetic (PopPK) analysis and exposure‐response analyses for the primary efficacy end point—acute graft‐versus‐host…”
Get full text

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models by Liu, Phillip C C, Koblish, Holly, Wu, Liangxing, Bowman, Kevin, Diamond, Sharon, DiMatteo, Darlise, Zhang, Yue, Hansbury, Michael, Rupar, Mark, Wen, Xiaoming, Collier, Paul, Feldman, Patricia, Klabe, Ronald, Burke, Krista A, Soloviev, Maxim, Gardiner, Christine, He, Xin, Volgina, Alla, Covington, Maryanne, Ruggeri, Bruce, Wynn, Richard, Burn, Timothy C, Scherle, Peggy, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Hollis, Gregory

“…Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes. Pharmacological targeting of FGFRs may…”
Get full text

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis by Punwani, Naresh, PhD, Scherle, Peggy, PhD, Flores, Robert, BSN, Shi, Jack, PhD, Liang, Jinjin, PhD, Yeleswaram, Swamy, PhD, Levy, Richard, MD, Williams, William, MD, Gottlieb, Alice, MD, PhD

“…Background Janus-associated kinases (JAKs) are involved in signal transduction from a variety of cytokines implicated in the pathogenesis of psoriasis,…”
Get full text

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies by Ji, Tao, Chen, Xuejun, Liu, Xiang, Yeleswaram, Swamy

“…Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat cholangiocarcinoma. A compartmental population pharmacokinetics model was…”
Get full text

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers by Shi, Jack G., Chen, Xuejun, Lee, Fiona, Emm, Thomas, Scherle, Peggy A., Lo, Yvonne, Punwani, Naresh, Williams, William V., Yeleswaram, Swamy

“…Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for…”
Get full text

Evaluation of drug-drug interactions of pemigatinib in healthy participants by Ji, Tao, Rockich, Kevin, Epstein, Noam, Overholt, Heather, Wang, Phillip, Chen, Xuejun, Punwani, Naresh, Yeleswaram, Swamy

“…Purpose Pemigatinib (INCB054828), a potent and selective oral fibroblast growth factor receptor 1–3 inhibitor, is a Biopharmaceutical Classification System…”
Get full text

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants by Li, Jia, Rockich, Kevin, Yuska, Brad, Zhou, Gongfu, Epstein, Noam, Punwani, Naresh, Chen, Xuejun, Yeleswaram, Swamy

“…Parsaclisib, a selective, potent phosphatidylinositol 3‐kinase delta inhibitor being developed for the treatment of cancer and autoimmune diseases, is…”
Get full text

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling by Ji, Tao, Chen, Xuejun, Yeleswaram, Swamy

“…Pemigatinib is a potent inhibitor of fibroblast growth factor receptor being developed for oncology indications. It is primarily metabolized by cytochrome P450…”
Get full text

Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects by Barbour, April M., Punwani, Naresh, Epstein, Noam, Landman, Robert, Cimino, Evan, Yuska, Brad, Wang, Phillip, He, Kevin, Chen, Xuejun, Yeleswaram, Swamy

“…Itacitinib is a potent, selective JAK‐1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft‐versus‐host disease (GVHD) in…”
Get full text

The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy by Zhang, Qiang, Zhang, Yan, Diamond, Sharon, Boer, Jason, Harris, Jennifer J, Li, Yu, Rupar, Mark, Behshad, Elham, Gardiner, Christine, Collier, Paul, Liu, Phillip, Burn, Timothy, Wynn, Richard, Hollis, Gregory, Yeleswaram, Swamy

“…The clinical development of fedratinib, a Janus kinase (JAK2) inhibitor, was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients…”
Get full text

Correction to: Evaluation of drug‑drug interactions of pemigatinib in healthy participants by Ji, Tao, Rockich, Kevin, Epstein, Noam, Overholt, Heather, Wang, Phillip, Chen, Xuejun, Punwani, Naresh, Yeleswaram, Swamy

Get full text

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 by Fridman, Jordan S, Scherle, Peggy A, Collins, Robert, Burn, Timothy C, Li, Yanlong, Li, Jun, Covington, Maryanne B, Thomas, Beth, Collier, Paul, Favata, Margaret F, Wen, Xiaoming, Shi, Jack, McGee, Ryan, Haley, Patrick J, Shepard, Stacey, Rodgers, James D, Yeleswaram, Swamy, Hollis, Greg, Newton, Robert C, Metcalf, Brian, Friedman, Steven M, Vaddi, Kris

“…Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis…”
Get full text

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib by Srinivas, Nithya, Barbour, April M., Epstein, Noam, Zhou, Gongfu, Petusky, Susan, Xun, Zhinyin, Yuska, Brad, Marbury, Thomas, Chen, Xuejun, Yeleswaram, Swamy, Punwani, Naresh

“…Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft‐versus‐host disease. The objective of this study was to assess…”
Get full text

Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications by DIAMOND, Sharon, BOER, Jason, MADUSKUIE, Thomas P, FALAHATPISHEH, Nikoo, YU LI, YELESWARAM, Swamy

“…An investigation was conducted to follow up on the apparent species-dependent toxicity reported for…”
Get full text

Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib by Barbour, April M., Rockich, Kevin, Cimino, Evan, Zhou, Gongfu, Leonetti‐Whalen, Caterina, Chen, Xuejun, Yeleswaram, Swamy, Epstein, Noam, Punwani, Naresh

“…Itacitinib is a potent, selective JAK‐1 inhibitor currently in development for the treatment of chronic graft‐vs‐host‐disease in combination with…”
Get full text

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies by Koblish, Holly, Li, Yun-Long, Shin, Niu, Hall, Leslie, Wang, Qian, Wang, Kathy, Covington, Maryanne, Marando, Cindy, Bowman, Kevin, Boer, Jason, Burke, Krista, Wynn, Richard, Margulis, Alex, Reuther, Gary W, Lambert, Que T, Dostalik Roman, Valerie, Zhang, Ke, Feng, Hao, Xue, Chu-Biao, Diamond, Sharon, Hollis, Greg, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Vaddi, Kris, Scherle, Peggy

“…The Proviral Integration site of Moloney murine leukemia virus (PIM) serine/threonine protein kinases are overexpressed in many hematologic and solid tumor…”
Get full text

The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers by Shi, Jack G., Chen, Xuejun, McGee, Ryan F., Landman, Robert R., Emm, Thomas, Lo, Yvonne, Scherle, Peggy A., Punwani, Naresh G., Williams, William V., Yeleswaram, Swamy

“…INCB018424 phosphate, a potent inhibitor of JAK enzymes with selectivity for JAK1&2, is in development for the treatment of myelofibrosis (MF). The oral dose…”
Get full text

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies by Gong, Xiaohua, Ji, Tao, Liu, Xiang, Chen, Xuejun, Yeleswaram, Swamy

“…Pemigatinib is a potent inhibitor of the fibroblast growth factor receptor (FGFR) family of receptors that is approved for the treatment of cholangiocarcinoma…”
Get full text

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis by Verstovsek, Srdan, Yeleswaram, Swamy, Hou, Kevin, Chen, Xuejun, Erickson‐Viitanen, Sue

“…Ruxolitinib is the first Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis, where its efficacy is often associated with cytopenia. It is…”
Get full text

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation by Fridman, Jordan S., Scherle, Peggy A., Collins, Robert, Burn, Timothy, Neilan, Claire L., Hertel, Denise, Contel, Nancy, Haley, Patrick, Thomas, Beth, Shi, Jack, Collier, Paul, Rodgers, James D., Shepard, Stacey, Metcalf, Brian, Hollis, Gregory, Newton, Robert C., Yeleswaram, Swamy, Friedman, Steven M., Vaddi, Kris

“…JAKs are required for signaling initiated by several cytokines (e.g., IL-4, IL-12, IL-23, thymic stromal lymphopoietin (TSLP), and IFNγ) implicated in the…”
Get full text